VEGFA and neoplasm: Regorafenib (Reg), a broad-spectrum kinase inhibitor, not only counters molecular escape pathways from VEGF inhibition but also bolsters anti-tumor immunity by reducing the infiltration of tumor-associated macrophages (TAMs) and altering TAM polarization [5,6].